COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke

Inclusion Criteria: * Ischemic stroke diagnosed within 48 hours from symptom onset; * Cerebral ischemic lesion observed on diffusion-weighted magnetic resonance imaging (DWI MRI); * Relevant atherothrombotic lesions on magnetic resonance angiography (MRA) or computed tomography angiography (CTA); * Study drug administration within 48 hours from symptom onset; * mRS score is 0-2 before the stroke. Exclusion Criteria: * Evidences of other relevant brain lesions such as Intracerebral hemorrhage (ICH) or brain tumor; * Suspicious of stroke due to small-vessel occlusion; * Stroke due to cardioembolism; * Clinical necessity of conventional angiography or intervention before the end of study; * Past history of ICH; * Bleeding diathesis or coagulopathy; * Chronic anemia (Hb\<8.0) or thrombocytopenia (PLT\<100K); * Chronic liver disease (AST\> 100 or ALT\>100); * Any other clinically relevant serious disease, including renal failure ( creatinine clearance\<30mL/min); * Allergy to Aspirin or clopidogrel; * Subjected to intervention or surgical treatments within 3 months; * Thrombolysis performed with rt-PA or UK after the stroke; * Participation in another clinical study within the previous 30 days; * Suspicious of poor drug compliance and requirements of the protocol; * Females who are pregnant, breast-feeding, or childbearing potential and not using medically acceptable and effective contraception. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.